Overview Dividends

(INDV) Indivior Ordinary Shares - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: GB00BN4HT335

Suboxone, Sublocade, Subutex, Opvee

EPS (Earnings per Share)

EPS Growth (3y CAGR): 314.97%
EPS Trend (3y Corr): 50.6%

Last SUE: 0.54σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 8.72%
Revenue Trend (3y Corr): 74.0%

Last SUE: 2.13σ
Qual. Beats: 4

Risk via 10d forecast
Volatility	58.8%
Value at Risk 5%th	79.8%
Relative Tail Risk	-17.40%

Reward TTM
Sharpe Ratio	2.36
Alpha	207.50

Character TTM
Hurst Exponent	0.565
Beta	0.702
Beta Downside	0.730

Drawdowns 3y
Max DD	69.89%
Mean DD	30.07%
Median DD	28.82%

Description: INDV Indivior Ordinary Shares November 10, 2025

Indivior PLC (NASDAQ: INDV) is a specialty biopharma focused on developing, manufacturing, and commercializing buprenorphine-based therapies for opioid dependence and related substance-use disorders across the United States, Europe, Canada, Australia, and other international markets.

Its flagship portfolio includes the monthly SUBLOCADE extended-release injection, SUBOXONE Film and Tablet (buprenorphine-naloxone sublingual formulations), SUBUTEX Tablet (buprenorphine monotherapy), and the OPVEE nasal spray for opioid-overdose reversal. The pipeline features INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 for moderate-to-severe OUD, and INDV-6001, a long-acting injectable being co-developed with Alar Pharmaceuticals.

In FY 2023, Indivior generated $1.04 billion in revenue, driven primarily by SUBLOCADE and SUBOXONE sales, while reporting a net loss of $145 million and maintaining $460 million of cash and marketable securities-sufficient to fund R&D through 2026 under current burn rates. The company’s growth outlook is tied to macro-drivers such as expanding Medicaid enrollment, ongoing opioid-crisis legislation that increases reimbursement for medication-assisted treatment, and a projected 6 % CAGR in the global OUD therapeutics market through 2030.

For a deeper quantitative view, consider using ValueRay’s analyst toolkit to model INDV’s cash-flow sensitivity to policy shifts and payer dynamics.

INDV Stock Overview

Market Cap in USD	4,033m
Sub-Industry	Biotechnology
IPO / Inception	2014-12-29
Return 12m vs S&P 500	168%
Analyst Rating	4.71 of 5

INDV Dividends

Currently no dividends paid

INDV Growth Ratios

Metric	Value
CAGR 3y	118.09%
CAGR/Max DD Calmar Ratio	1.69
CAGR/Mean DD Pain Ratio	3.93
Current Volume	1407.6k
Average Volume	1857.4k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (166.0m TTM) > 0 and > 6% of Revenue (6% = 70.9m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 28.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -3.64% (prev -13.79%; Δ 10.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.14 (>3.0%) and CFO 194.1m > Net Income 166.0m (YES >=105%, WARN >=100%)

Net Debt (-89.0m) to EBITDA (315.0m) ratio: -0.28 <= 3.0 (WARN <= 3.5)

Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (129.0m) change vs 12m ago -3.41% (target <= -2.0% for YES)

Gross Margin 82.81% (prev 79.96%; Δ 2.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 82.01% (prev 80.76%; Δ 1.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.73 (EBITDA TTM 315.0m / Interest Expense TTM 52.0m) >= 6 (WARN >= 3)

Altman Z'' 0.19

(A) -0.03 = (Total Current Assets 922.0m - Total Current Liabilities 965.0m) / Total Assets 1.42b

(B) -0.24 = Retained Earnings (Balance) -346.0m / Total Assets 1.42b

(D) -0.19 = Book Value of Equity -316.0m / Total Liabilities 1.62b

Total Rating: 0.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.65

1. Piotroski 7.0pt

2. FCF Yield 3.42%

3. FCF Margin 11.43%

4. Debt/Equity -1.72

5. Debt/Ebitda -0.28

6. ROIC - WACC (= 633.1)%

7. RoE -60.42%

8. Rev. Trend 74.02%

9. EPS Trend 50.57%

What is the price of INDV shares?

As of November 21, 2025, the stock is trading at USD 31.77 with a total of 1,407,613 shares traded.
Over the past week, the price has changed by +6.50%, over one month by +30.79%, over three months by +31.55% and over the past year by +200.28%.

Is INDV a buy, sell or hold?

Indivior Ordinary Shares has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy INDV.

Strong Buy: 5
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the INDV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	36.7	15.5%
Analysts Target Price	36.7	15.5%
ValueRay Target Price	37.2	17.2%

INDV Fundamental Data Overview November 20, 2025

Market Cap USD = 4.03b (4.03b USD * 1.0 USD.USD)
P/E Trailing = 32.9184
P/E Forward = 10.0604
P/S = 3.418
P/B = 145.2492
Beta = 1.12
Revenue TTM = 1.18b USD
EBIT TTM = 298.0m USD
EBITDA TTM = 315.0m USD
Long Term Debt = 304.0m USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 356.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.0m USD (from netDebt column, last quarter)
Enterprise Value = 3.94b USD (4.03b + Debt 356.0m - CCE 445.0m)
Interest Coverage Ratio = 5.73 (Ebit TTM 298.0m / Interest Expense TTM 52.0m)
FCF Yield = 3.42% (FCF TTM 135.0m / Enterprise Value 3.94b)
FCF Margin = 11.43% (FCF TTM 135.0m / Revenue TTM 1.18b)
Net Margin = 14.06% (Net Income TTM 166.0m / Revenue TTM 1.18b)
Gross Margin = 82.81% ((Revenue TTM 1.18b - Cost of Revenue TTM 203.0m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 82.78%)
Tobins Q-Ratio = 2.79 (Enterprise Value 3.94b / Total Assets 1.42b)
Interest Expense / Debt = 3.37% (Interest Expense 12.0m / Debt 356.0m)
Taxrate = -13.51% (negative due to tax credits) (-5.00m / 37.0m)
NOPAT = 338.3m (EBIT 298.0m * (1 - -13.51%)) [negative tax rate / tax credits]
Current Ratio = 0.96 (Total Current Assets 922.0m / Total Current Liabilities 965.0m)
Debt / Equity = -1.72 (negative equity) (Debt 356.0m / totalStockholderEquity, last quarter -207.0m)
Debt / EBITDA = -0.28 (Net Debt -89.0m / EBITDA 315.0m)
Debt / FCF = -0.66 (Net Debt -89.0m / FCF TTM 135.0m)
Total Stockholder Equity = -274.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.72% (Net Income 166.0m / Total Assets 1.42b)
RoE = -60.42% (negative equity) (Net Income TTM 166.0m / Total Stockholder Equity -274.8m)
RoCE = 1019 % (out of range, set to none) (EBIT 298.0m / Capital Employed (Equity -274.8m + L.T.Debt 304.0m))
RoIC = 641.3% (NOPAT 338.3m / Invested Capital 52.8m)
WACC = 8.21% (E(4.03b)/V(4.39b) * Re(8.60%) + D(356.0m)/V(4.39b) * Rd(3.37%) * (1-Tc(-0.14)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.67%
[DCF Debug] Terminal Value 67.98% ; FCFE base≈135.0m ; Y1≈88.6m ; Y5≈40.5m
Fair Price DCF = 5.81 (DCF Value 725.9m / Shares Outstanding 125.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 50.57 | EPS CAGR: 315.0% | SUE: 0.54 | # QB: 0
Revenue Correlation: 74.02 | Revenue CAGR: 8.72% | SUE: 2.13 | # QB: 4

Additional Sources for INDV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle